Citius Pharma Q2 2026: $5.6M H1 LYMPHIR revenue, 80% gross margins; raises $36.5M at Citius Oncology

Citius Pharmaceuticals, Inc.

2026-Q2 EPS reported -$1.34 revenue$5,611,409

Net product revenue $1.7M in Q2 (launch quarter); $5.6M in H1 2026 vs. zero a year ago.
Payer coverage near 100% of commercial lives; 83% of target accounts on formulary or in review.
Citius Oncology secured up to $36.5M debt/equity; Citius Pharma raised $5M direct offering.
Net loss $21.2M in Q2 ($0.95/share) vs. $10.9M a year ago; includes $19.7M CMO cancellation charge.
First LYMPHIR shipment to Europe via Uniphar; positive Phase 1 combo data with pembrolizumab and pre-CAR-T.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Citius Pharmaceuticals, Inc. reported fiscal second quarter ended March 31, 2026 results: revenue Net product revenues of $1.7 million for the three months ended March 31, 2026.

Period: fiscal second quarter ended March 31, 2026
Revenue: Net product revenues of $1.7 million for the three months ended March 31, 2026
Result: reported results

Exact text from the filing

Net product revenues of $1.7 million for the three months ended March 31, 2026

View on SEC.gov

Browse all earnings releases →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-057876

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.